慈丹胶囊治疗原发性肝癌Ⅳ期86例的临床研究

Clinical Observation of Effect of Ci Dan Capsule on 63 Patients of Primary Liver Carcinoma of phase Ⅳ

目的:观察慈丹胶囊治疗原发性肝癌Ⅳ期的疗效及安全性。方法:采用开放随机分组的方法,将160例原发性肝癌患者随机分为2组。治疗组86例,给予慈丹胶囊5粒/次,每日4次。对照组74例,给予慈丹胶囊治疗的同时,加服化疗药。1个月为1个疗程,3个疗程后,评估慈丹胶囊治疗原发性肝癌的疗效与安全性。结果:对照组各瘤体观察疗效、分期与疗效方面优于治疗组,肝肾功能、血象变化、不良反应方面治疗组优于对照组。结论:慈丹胶囊治疗原发性肝癌安全有效。

Objective：To explore efficacy and safety of Ci Dan capsule for treatment of primary liver carcinoma of phase Ⅳ. Methods： Patients of primary liver carcinoma of phaseiv （n = 160） were open randomized to treatment group （n = 86 ）, to take Ci Dan capsules, 5 capsules each time, 4 times daily, and control group （ n = 74） to take Ci Dan capsules on top of chemotherapy. After 3 courses of treatment （3 months）, efficacy and safety of Ci Dan capsule were evaluated. Results：The control group was better in observed efficacy, phase classification, while the treatment was better liver and kidney functional improvement, hematology parameters and safety. Conclusion ： Ci Dan capsule is effective and safe in the treatment of primary liver carcinoma.